Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | CFTR | P13569 | 4/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | TPMT | P51580 | 1/20 | 0.36 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.36 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.35 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28491736 | 0.87 | POLB (0.44) | HSD17B10POLBL3MBTL1CFTRMAPK8 | |
| SCHEMBL28495356 | 0.85 | NPSR1 (0.42) | HSD17B10POLBL3MBTL1CFTRMAPK8 | |
| SCHEMBL21559955 | 0.81 | POLB (0.41) | POLBL3MBTL1CFTRTDP1MAPK8 | |
| SCHEMBL24291812 | 0.77 | HSD17B10 (0.47) | HSD17B10POLBLCKFYNTDP1 | |
| SCHEMBL29656639 | 0.77 | HSD17B10 (0.47) | HSD17B10POLBLCKFYNTDP1 | |
| SCHEMBL2372350 | 0.76 | CFTR (0.60) | CFTR | |
| SCHEMBL20745689 | 0.75 | TPMT (0.41) | HSD17B10POLBL3MBTL1TPMTALDH1A1 | |
| SCHEMBL22791078 | 0.75 | CFTR (0.53) | POLBCFTRTDP1 | |
| SCHEMBL23616411 | 0.75 | HSD17B10 (0.41) | HSD17B10POLBL3MBTL1LCKFYN | |
| SCHEMBL28762468 | 0.75 | POLB (0.41) | POLBL3MBTL1CFTRTDP1MAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3668863-B1 | TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS INC (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-112110918-B | Spiro substituted pyrimido cyclic compounds, process for their preparation and their use in medicine | 劲方医药科技(上海)有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11584734-B2 | Tricyclic compounds as histone methyltransferase inhibitors | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2023-01-05 | — | — | US | disclosed |
| CN-112110918-A | Spiro-substituted pyrimido-cyclic compounds, preparation method and medical application thereof | 劲方医药科技(上海)有限公司 | 2020-12-22 | — | — | CN | disclosed |
| US-20200361896-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. | 2020-11-19 | — | — | US | disclosed |
| CN-111372927-A | Tricyclic compounds as histone methyltransferase inhibitors | 全球血液疗法股份有限公司 | 2020-07-03 | — | — | CN | disclosed |
| EP-3668863-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS | Global Blood Therapeutics, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| WO-2019036384-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019036377-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYL-TRANSFERASE INHIBITORS | GLOBAL BLOOD THERAPEUTICS, INC. (US) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002351-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | HSD17B10 1376/4885POLB 1034/4885L3MBTL1 52/4885 |
| US-11661410-B2 | Tricyclic compounds as histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | HSD17B10 1376/4885POLB 1034/4885L3MBTL1 52/4885 |
| US-11584734-B2 | Tricyclic compounds as histone methyltransferase inhibitors | EHMT1, EHMT2, BMI1 | HSD17B10 1125/4885POLB 871/4885L3MBTL1 97/4885 |
| US-20200361896-A1 | TRICYCLIC COMPOUNDS AS HISTONE METHYLTRANSFERASE INHIBITORS | EHMT1, EHMT2, BMI1 | HSD17B10 1125/4885POLB 871/4885L3MBTL1 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.